Stock Track | Amgen Soars 5.30% Intraday on Upbeat 2026 Profit Forecast and Strong Q4 Results

Stock Track02-04 22:52

Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.

The sharp rise follows the company's release of fourth-quarter financial results that exceeded analyst expectations, with adjusted earnings per share of $5.29 beating the estimate of $4.73. Revenue for the quarter reached $9.9 billion, surpassing the anticipated $9.5 billion. Furthermore, Amgen provided an optimistic profit forecast for 2026, projecting adjusted earnings per share between $21.60 and $23, above the average analyst estimate of $22.09.

Analysts have reacted positively to the report, with several brokerages raising their price targets on the stock. The strong performance was attributed to robust sales from key products like Prolia, Evenity, Repatha, and Vectibix. Additionally, investor sentiment is bolstered by optimism surrounding Amgen's pipeline, particularly the potential of its experimental weight-loss drug MariTide, which is seen as a long-term growth driver.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155147238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155147238","market":"hk","top_or_hot":-1,"title":"Stock Track | Amgen Soars 5.30% Intraday on Upbeat 2026 Profit Forecast and Strong Q4 Results","media":"Stock Track","content":"<p>Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.</p><p>The sharp rise follows the company's release of fourth-quarter financial results that exceeded analyst expectations, with adjusted earnings per share of $5.29 beating the estimate of $4.73. Revenue for the quarter reached $9.9 billion, surpassing the anticipated $9.5 billion. Furthermore, Amgen provided an optimistic profit forecast for 2026, projecting adjusted earnings per share between $21.60 and $23, above the average analyst estimate of $22.09.</p><p>Analysts have reacted positively to the report, with several brokerages raising their price targets on the stock. The strong performance was attributed to robust sales from key products like Prolia, Evenity, Repatha, and Vectibix. Additionally, investor sentiment is bolstered by optimism surrounding Amgen's pipeline, particularly the potential of its experimental weight-loss drug MariTide, which is seen as a long-term growth driver.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amgen Soars 5.30% Intraday on Upbeat 2026 Profit Forecast and Strong Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amgen Soars 5.30% Intraday on Upbeat 2026 Profit Forecast and Strong Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.</p><p>The sharp rise follows the company's release of fourth-quarter financial results that exceeded analyst expectations, with adjusted earnings per share of $5.29 beating the estimate of $4.73. Revenue for the quarter reached $9.9 billion, surpassing the anticipated $9.5 billion. Furthermore, Amgen provided an optimistic profit forecast for 2026, projecting adjusted earnings per share between $21.60 and $23, above the average analyst estimate of $22.09.</p><p>Analysts have reacted positively to the report, with several brokerages raising their price targets on the stock. The strong performance was attributed to robust sales from key products like Prolia, Evenity, Repatha, and Vectibix. Additionally, investor sentiment is bolstered by optimism surrounding Amgen's pipeline, particularly the potential of its experimental weight-loss drug MariTide, which is seen as a long-term growth driver.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMGN","symbol_name":"安进","start_time":0,"source_url":"","article_id":"1155147238","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155147238","pubTimestamp":1770216764,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.The sharp rise follows the company's release of fourth-quarter financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMGN":"安进"},"translate_title":"个股追踪|安进盘中大涨5.30%，2026年盈利预测乐观，Q4业绩强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.The sharp rise follows the company's release of fourth-quarter financial results that exceeded analyst expectations, with adjusted earnings per share of $5.29 beating the estimate of $4.73. Revenue for the quarter reached $9.9 billion, surpassing the anticipated $9.5 billion. Furthermore, Amgen provided an optimistic profit forecast for 2026, projecting adjusted earnings per share between $21.60 and $23, above the average analyst estimate of $22.09.Analysts have reacted positively to the report, with several brokerages raising their price targets on the stock. The strong performance was attributed to robust sales from key products like Prolia, Evenity, Repatha, and Vectibix. Additionally, investor sentiment is bolstered by optimism surrounding Amgen's pipeline, particularly the potential of its experimental weight-loss drug MariTide, which is seen as a long-term growth driver.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155147238","isCrawlerRequest":true}